A Phase 2 interventional study of gemcitabine and cisplatin in Biliary Tract Cancer, sponsored by Eli Lilly and Company. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2009-11-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies testing gemcitabine in Biliary Tract Neoplasms — 9 open to participants now, 13 under way, 2 of them phase 3. Gemcitabine · Biliary Tract Neoplasms.
Among the 49 studies testing gemcitabine in Biliary Tract Neoplasms, this one is the 11th largest by enrollment, is one of 2 that started in 2006, is one of 28 in phase 2, and was the 4th registered.
521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.
Browse Biliary Tract Neoplasms studies →9 of the 49 studies testing gemcitabine in Biliary Tract Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Peking University · Sites in China
Ages 18–80
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
Jinbo Yue · Sites in China
Ages 18–75
University of Maryland, Baltimore · Sites in United States
Ages 21+
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · Sites in China
Ages 18–75
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 141 Biliary Tract Neoplasms studies recruiting now, 81 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 35 · Phase 3 4
First in 2001; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 58 across 429 interventional studies indexed under Biliary Tract Neoplasms.
Median enrollment 44 across the 49 interventional studies. Of the 31 that completed or were terminated, 11 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 49 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 4 studies filed under Biliary Tract Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing gemcitabine in Biliary Tract Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02632305AHS Cancer Control AlbertaA Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer | 2026-12 |
| NCT07831993The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer | 2027-06-30 |
| NCT07030140Jinbo YuePhase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 49 studies testing gemcitabine in Biliary Tract Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To investigate efficacy and safety of gemcitabine combined with cisplatin and of gemcitabine alone by comparison in patients with advanced biliary tract cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal. Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
Drug: gemcitabine · Drug: cisplatin
Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
Drug: gemcitabine
1000 milligrams per square meter (mg/m2), intravenous (IV)
Also known as: LY188011, Gemzar
25 milligrams per square meter (mg/m2), intravenous (IV)
Percentage of Patients Alive at 1 Year (1-Year Survival Rate)
Percentage of patients alive at 1 year.
Time frame: 1 year
Tumor Response
Response Evaluation Criteria In Solid Tumors - define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Complete response (CR) = disappearance of all target lesions; Partial Response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria.
Time frame: baseline to measured progressive disease (up to 2 years)
Progression Free Survival
The period from study entry until disease progression, death or date of last contact.
Time frame: baseline to measured progressive disease (up to 2 years)
Survival Time
Data of patients lost to follow-up were censored at the last date of confirmation of their survival.
Time frame: baseline to date of death due to any cause (up to 2 years)
| Milestone | Gemcitabine + Cisplatin | Gemcitabine |
|---|---|---|
| Started | 42 | 42 |
| Received at least one dose of study drug | 41 | 42 |
| Completed | 3 | 2 |
| Not completed | 39 | 40 |
| Withdrew: Unequivocal disease progression | 25 | 34 |
| Withdrew: Next cycle not started | 4 | 0 |
| Withdrew: Adverse event | 7 | 3 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Physician decision | 2 | 0 |
Percentage of patients alive at 1 year.
| percentage of participants | Gemcitabine + Cisplatin | Gemcitabine |
|---|---|---|
| Percentage of Patients Alive at 1 Year (1-Year Survival Rate) | 39 | 31 |
Response Evaluation Criteria In Solid Tumors - define when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. Complete response (CR) = disappearance of all target lesions; Partial Response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable Disease (SD) = small changes that do not meet above criteria.
| participants | Gemcitabine + Cisplatin | Gemcitabine |
|---|---|---|
| Complete Response | 0 | 0 |
| Partial Response | 8 | 5 |
| Stable Disease | 20 | 16 |
| Progressive Disease | 9 | 17 |
| Not Evaluable | 4 | 4 |
The period from study entry until disease progression, death or date of last contact.
| months | Gemcitabine + Cisplatin | Gemcitabine |
|---|---|---|
| Progression Free Survival | 5.8 (4.1 to 8.2) | 3.7 (2.1 to 5.3) |
Data of patients lost to follow-up were censored at the last date of confirmation of their survival.
| months | Gemcitabine + Cisplatin | Gemcitabine |
|---|---|---|
| Survival Time | 11.2 (9.1 to 12.5) | 7.7 (6.1 to 11.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine + Cisplatin | — | 9/41 (22%) | 41/41 (100%) |
| Gemcitabine | — | 17/42 (40.5%) | 42/42 (100%) |
| Event | Gemcitabine + Cisplatin | Gemcitabine |
|---|---|---|
| CholangitisHepatobiliary disorders | 4/41 | 8/42 |
| Jaundice cholestaticHepatobiliary disorders | 2/41 | 4/42 |
| Liver abscessInfections and infestations | 2/41 | 0/42 |
| AnaemiaBlood and lymphatic system disorders | 1/41 | 0/42 |
| Duodenal stenosisGastrointestinal disorders | 1/41 | 0/42 |
| HaemobiliaHepatobiliary disorders | 1/41 | 0/42 |
| Platelet count decreasedInvestigations | 1/41 | 0/42 |
| Cerebral infarctionNervous system disorders | 1/41 | 0/42 |
| Renal failure acuteRenal and urinary disorders | 1/41 | 0/42 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 1/41 | 1/42 |
| Event | Gemcitabine + Cisplatin | Gemcitabine |
|---|---|---|
| White blood cell count decreasedInvestigations | 36/41 | 29/42 |
| Haemoglobin decreasedInvestigations | 35/41 | 36/42 |
| Neutrophil count decreasedInvestigations | 34/41 | 29/42 |
| Platelet count decreasedInvestigations | 33/41 | 32/42 |
| AnorexiaMetabolism and nutrition disorders | 33/41 | 26/42 |
| Red blood cell count decreasedInvestigations | 31/41 | 33/42 |
| NauseaGastrointestinal disorders | 28/41 | 18/42 |
| PyrexiaGeneral disorders | 18/41 | 25/42 |
| FatigueGeneral disorders | 24/41 | 21/42 |
| Haematocrit decreasedInvestigations | 24/41 | 23/42 |
| Age Continuous(years) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| Mean | 63.7 ± 10.1 | 67.0 ± 6.9 | 65.4 ± 8.7 |
| Sex: Female, Male(Participants) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| Female | 23 | 21 | 44 |
| Male | 18 | 21 | 39 |
| Region of Enrollment(participants) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| Japan | 41 | 42 | 83 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| 0 - Fully Active | 34 | 28 | 62 |
| 1 - Ambulatory, Restricted Strenuous Activity | 7 | 14 | 21 |
| Primary Tumor(participants) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| Extrahepatic Bile Duct | 8 | 11 | 19 |
| Intrahepatic Bile Duct | 14 | 14 | 28 |
| Gallbladder | 15 | 17 | 32 |
| Papilla | 4 | 0 | 4 |
| Tumor Histological Type(participants) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| Adenocarcinoma | 39 | 41 | 80 |
| Adenosquamous Cancer | 2 | 1 | 3 |
| Body Surface Area(square meter (m^2)) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| Mean | 1.555 ± 0.195 | 1.523 ± 0.158 | 1.539 ± 0.177 |
| Height(centimeters (cm)) | Gemcitabine + Cisplatin | Gemcitabine | Total |
|---|---|---|---|
| Mean | 159.80 ± 8.75 | 156.67 ± 8.62 | 158.21 ± 8.77 |
1 further baseline measures are reported on the registry.
The record gives a start of Sep 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine